FDA Authorizes Third Dose of Pfizer-BioNTech and Moderna COVID-19 Vaccines for Immunocompromised Individuals

The U.S. Food and Drug Administration has amended the emergency use authorizations (EUAs) for the COVID-19 vaccine developed jointly by Pfizer Inc. (New York, NY, USA) and Biopharmaceutical New Technologies (BioNTech Mainz, Germany), as well as Moderna, Inc.’s (Cambridge, MA, USA) mRNA-1273 COVID-19 vaccine to allow for their additional dose in certain immunocompromised individuals.

Such immunocompromised individuals specifically comprise solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. The amended EUA does not apply to people who are not immunocompromised. The Pfizer-BioNTech COVID-19 vaccine is currently authorized for emergency use in individuals ages 12 and older, and the Moderna COVID-19 vaccine is authorized for emergency use in individuals ages 18 and older. Both vaccines are administered as a series of two shots: the Pfizer-BioNTech COVID-19 vaccine is administered three weeks apart, and the Moderna COVID-19 vaccine is administered one month apart.


The authorizations for these vaccines have been amended to allow for an additional, or third, dose to be administered at least 28 days following the two-dose regimen of the same vaccine to individuals 18 years of age or older (ages 12 or older for Pfizer-BioNTech) who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. People who are immunocompromised in a manner similar to those who have undergone solid organ transplantation have a reduced ability to fight infections and other diseases, and they are especially vulnerable to infections, including COVID-19. The FDA has evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna Vaccines in these individuals and determined that the administration of third vaccine doses may increase protection in this population.

“The country has entered yet another wave of the COVID-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease. After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna Vaccines,” said Acting FDA Commissioner Janet Woodcock, M.D. “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19. As we’ve previously stated, other individuals who are fully vaccinated are adequately protected and do not need an additional dose of COVID-19 vaccine at this time. The FDA is actively engaged in a science-based, rigorous process with our federal partners to consider whether an additional dose may be needed in the future.”

Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies
Moderna, Inc.